From an Outcast to a Standard of Care in Immuno-Oncology History

Dr. Israel Lowy, Head of Oncology Clinical Development at Regeneron Pharmaceuticals (REGN), reflected on the early history of immunotherapy at the BIO 2026 Conference. He recalled how, despite initial skepticism from the academic community, he believed in the gut feeling that blocking the mechanisms by which cancer cells evade the immune system was crucial. He continued his research diligently since his time at Medarex. This research laid the critical foundation for the development of blockbuster immune checkpoint inhibitors such as Merck's (MRK) Keytruda (pembrolizumab) and Bristol Myers Squibb's (BMY) Opdivo (nivolumab). What once seemed like a reckless endeavor has now become the standard of care in global cancer treatment, fundamentally changing the paradigm of cancer therapy.

Pipeline Crisis Triggered by Late-Stage Phase 3 Failure

However, Regeneron's independent immuno-oncology pipeline has recently faced a painful setback. The combination therapy of fianlimab, Regeneron's independently developed LAG-3 inhibitor (Lymphocyte-activation Gene 3 Inhibitor) candidate, and libtayo (cemiplimab), a PD-1 inhibitor, failed to demonstrate statistically significant improvement in progression-free survival (PFS), the primary endpoint, in a Phase 3 clinical trial for first-line treatment of melanoma. While the high-dose group showed a median PFS of 11.5 months, compared to 6.4 months for the control group of Keytruda monotherapy, the improvement was not statistically significant, causing a sharp drop in the stock price and disappointing the market. This is considered another example of the limitations of second-generation immune checkpoint inhibitors that target a single target.

Large-Scale Expansion of Co-Development for Targeting the Tumor Microenvironment

To overcome this clinical failure and secure its next-generation growth engine, Regeneron is focusing on antibody-drug conjugates (ADCs) and the introduction of new technologies that target the tumor microenvironment. First, Regeneron expanded its conditional activation bispecific antibody cancer therapy co-development agreement with CytomX Therapeutics (CTMX) to a maximum of $4 billion. CytomX's Probody platform can induce antibody activation only in the tumor microenvironment, which can significantly reduce the systemic toxicity associated with existing immunotherapies. This partnership expansion is a strategic choice to control the complex microenvironment around cancer cells and maximize the immune system's efficiency in attacking cancer.

New Partnership to Target Intracellular Undruggable Targets

In addition, Regeneron entered into a new strategic research collaboration agreement with Parabilis Medicines for up to $2.3 billion, expanding into areas with high unmet medical needs. This deal includes an upfront payment of $50 million and a future equity investment of $75 million, and involves combining Parabilis' cell-penetrating alpha-helical structural peptide (Helicon) platform technology with Regeneron's antibody engineering technology. This will enable the development of next-generation antibody-Helicon conjugates (AHCs) that directly target intracellular targets, which have been difficult to access with existing antibody therapies. By proactively investing a large sum of money in promising new platform technologies to overcome the impact of the late-stage clinical failure, Regeneron aims to maintain its technological leadership in the immuno-oncology market.